Helicobacter pylori eradication in childhood after failure of initial treatment: Advantage of quadruple therapy with nifuratel to furazolidone

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 9, 2005, Pages 881-887

  Nijevitch, A A ^a   Shcherbakov, P L ^b   Sataev, V U ^a   Khasanov, R Sh ^a   Al Khashash, R ^a   Tuygunov, M M ^c  

^a Children's Republican Hospital Ufa   (Russian Federation)

^b Scientific Center of Children's Health   (Russian Federation)

^c Research Institute of Vaccine and Serum (Microgen)   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; FURAZOLIDONE; METRONIDAZOLE; NIFURATEL; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADOLESCENT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; ERADICATION THERAPY; EVALUATION; FATIGUE; FECES; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; TASTE DISORDER; TONGUE DISEASE; TREATMENT FAILURE; URINE; VOMITING;

ADOLESCENT; AMOXICILLIN; ANTACIDS; ANTI-BACTERIAL AGENTS; CHILD; DRUG THERAPY, COMBINATION; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; NIFURATEL; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTON PUMPS; TREATMENT OUTCOME;

EID: 27644590456     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02656.x     Document Type: Article

References (37)

1. Vandenplas Y, Blecker U. Helicobacter pylori infection in children. Acta Paediatr 1998; 87: 1105-12.
2. Azarow K, Kim P, Shandling B, Ein S. A 45-year experience with surgical treatment of peptic ulcer disease in children. J Pediatr Surg 1996; 31: 750-3.
3. Stringer MD, Veysi VT, Puntis JWL, Batcup G, Dixon MF. Gastroduodenal ulcers in the Helicobacter pylori era. Acta Paediatr 2000; 89: 1181-5.
4. Kneepkens CMF. Peptic ulcer disease in childhood. Acta Endosc 1994; 24: 169-81.
5. Dohil R, Israel DM, Hassal E. Effective 2-wk therapy for Helicobacter pylori disease in children. Am J Gastroenterol 1997; 92: 244-7.
6. Shcherbakov PL, Filin VA, Volkov IA, Tatarinov PA, Belousov YB. A randomized comparison of triple therapy Helicobacter pylori eradication regimens in children with peptic ulcers. J Int Med Res 2001; 29: 147-53.
7. Gosciniak GM, Iwanczak B, Przondo-Mordarska A. Grabinska J, Iwanczak F. Increase in resistance to metronidazole and clarithromycin of Helicobacter pylori strains isolated from children before and after treatment in the time span of 1997-2001. Gut 2002; 51 (Suppl. 11): A89.
8. Isakov VA, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z. Furazolidone-containing triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002; 16: 1277-82.
9. Nakayama Y, Graham DY. Helicobacter pylori infection: diagnosis and treatment. Expert Rev Anti-infect Ther 2004; 2: 599-610.
10. Queiroz DMM, Moura SB, Mendes EN, Rocha GA, Barbosa AJA, Carvalho AST. Effect of Helicobacter pylori eradication on G-cell and D-cell density in children. Lancet 1994; 343: 1191-3.
11. Nijevitch AA, Khasanov RS, Sataev VU. Ranitidine bismuth citrate plus amoxicillin and furazolidone in the eradication of H. pylori in children. Gut 2001; 49 (Suppl. 11): A77.
12. Shcherbakov PL, Vartapetova E, Nijevitch AA, et al. Safety of bismuth therapy in H. pylori positive children. Helicobacter 2003; 8: 455.
13. Mendling W, Mailland F. Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections. A review. Arzneimittelforschung 2002; 52: 8-13.
14. Hamilton-Miller JM, Brumfitt W. Comparative in vitro activity of five nitrofurans. Chemotherapy 1978; 24: 161-5.
15. Mitchell HM, Bohane TD, Tobias V, et al. Helicobacter pylori infection in children: potential clues to pathogenesis. J Pediatr Gastroenterol Nutr 1993; 16: 120-5.
16. Oderda G, Ponzetto A, Boero M, et al. Family treatment of symptomatic children with Helicobacter pylori infection. Ital J Gastroenterol Hepatol 1997; 29: 509-14.
17. Gisbert JP, Gisbert JL, Marcos S, Garcia Gravalos R, Carpio D, Pajares JM. Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999; 13: 1311-6.
18. Nijevitch AA, Farztdinov KM, Sataev VU, et al. Helicobacter pylori infection in childhood: results of management with ranitidine bismuth citrate plus amoxicilline and tinidazole. J Gastroenterol Hepatol 2000; 15: 1243-50.
19. Koudryavtseva L, Isakov VA, Ivanikov IO, Zaitseva SV. Evolution of H. pylori primary resistance to antimicrobial agents in Moscow (Russia) in 1996-1998. Gut 2000; 47 (Suppl. 1): A8.
20. Radhakrishnan S, Al Nakib B, Kalaoui M, Patric J. Helicobacter pylori-associated gastritis in Kuwait: endoscopy-containing study in symptomatic and asymptomatic children. J Pediatr Gastroenterol Nutr 1993; 16: 126-9.
21. Guo C-Y, Wu Y-B, Liu H-L, Wu J-Y, Zhong M-Z. Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. World J Gastroenterol 2004; 10: 747-9.
22. Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults world wide: a meta-analysis. Int J Epidemiol 2002; 31: 128-39.
23. Malekzadeh R, Ansari R, Vahedi H, et al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14: 299-303.
24. Graham KS, Graham DY. Contemporary Diagnosis and Management of H. pylori-associated Gastrointestinal Diseases. Newtown: Handbooks in Health Care Co., 2002.
25. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson S-Y, El Zimaity HMT. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000; 14: 211-5.
26. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990; 34: 1637-41.
27. Kwon DH, Lee M, Kim JJ, et al. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother 2001; 45: 306-8.
28. Sisson G, Goodwin A. Raudonikiene A, et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother 2002; 46: 2116-23.
29. Fakheri H, Malekzadeh R, Merat S, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001; 15: 411-6.
30. Fakheri H, Merat S, Hosseini V, Malekzadeh R. Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19: 89-93.
31. Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F, et al. The efficacy of furazolidone-containing quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-containing quadruple therapy. Med Sci Monit 2003; 9: 105-8.
32. Oderda G. Management of Helicobacter pylori infection in children. Gut 1998; 43 (Suppl. 1): S10-3.
33. Oderda G. Cure of Helicobacter pylori in children. Helicobacter 1997; 2 (Suppl. 1): S73-6.
34. Walsh D, Goggin N, Rowland M, Durnin M, Moriarty S, Drumm B. One week treatment for Helicobacter pylori infection. Arch Dis Child 1997; 76: 352-5.
35. Gormally SM, Prakash N, Durnin MT, et al. Association of symptoms with Helicobacter pylori infection in children. J Pediatr 1995; 126: 853-6.
36. Dore MP, Marras L, Maragkoudakis E, et al. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter 2003; 8: 307-9.
37. Perri F, Villani MR, Quitadamo M, Annese V, Niro GA, Andriulli A. Ranitidine bismuth citrate-containing triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? Aliment Pharmacol Ther 2001; 15: 1017-22.